Dipartimento di Scienze del Farmaco, Università degli Studi di Padova, Padua, Italy.
Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, Italy.
Atherosclerosis. 2016 Oct;253:214-224. doi: 10.1016/j.atherosclerosis.2016.07.910. Epub 2016 Jul 22.
Proprotein convertase subtilisin kexin type 9 (PCSK9) induces degradation of the low-density lipoprotein-receptor (LDLR). Smooth muscle cells (SMCs) in human atherosclerotic plaques and cultured SMCs express PCSK9. The present study aimed at defining the role of PCSK9 on vascular response to injury.
Carotid neointimal lesions were induced by positioning a non-occlusive collar in PCSK9 knock-out (PCSK9) and wild type littermate (PCSK9) mice.
In PCSK9 mice, we observed a significantly less intimal thickening (p < 0.05), a lower intimal media ratio (p < 0.02), and a tendency to higher lumen area, compared to PCSK9 mice. When compared with PCSK9, lesions of PCSK9 mice had a higher content of SMCs (p < 0.05) and collagen (p < 0.05), while no difference was observed in the accumulation of macrophages. PCSK9 was detectable in both left and right carotids artery in regions occupied by medial and neointimal SMCs. SMCs freshly isolated from PCSK9, when compared to PCSK9 cells, showed higher levels of α-smooth muscle actin (α-SMA; 2.24 ± 0.36 fold; p < 0.01) and myosin heavy chain II (MHC-II; 8.65 ± 1.55 fold; p < 0.01), and lower levels of caldesmon mRNA(-54 ± 14%; p < 0.01). PCSK9 cells also showed a slower proliferation rate, and an impaired migratory capacity and G1/S progression of the cell cycle. The reconstitution of PCSK9 expression, by retroviral infection of PCSK9 SMCs, led to a downregulation of α-SMA (-56 ± 2%; p < 0.01), MHC-II (-45% ± 25.5 fold: p = 0.06) and calponin (-25% ± 0.8 fold: p < 0.05) and induction of caldesmon mRNA (1.46 ± 0.3 fold; p < 0.05). Proliferation rate of SMCs PCSK9 was significantly lower compared to PCSK9 reconstituted cells.
Taken together, the present results suggest that PCSK9, by sustaining SMC synthetic phenotype, proliferation, and migration, may play a pro-atherogenic role in the arterial wall.
前蛋白转化酶枯草溶菌素 9(PCSK9)诱导低密度脂蛋白受体(LDLR)降解。人动脉粥样硬化斑块中的平滑肌细胞(SMCs)和培养的 SMCs 表达 PCSK9。本研究旨在定义 PCSK9 在血管损伤反应中的作用。
通过在 PCSK9 敲除(PCSK9)和野生型同窝仔(PCSK9)小鼠中定位非闭塞颈圈来诱导颈动脉内膜新生病变。
与 PCSK9 相比,PCSK9 小鼠的内膜增厚明显减少(p<0.05),内膜中膜比降低(p<0.02),管腔面积有增高趋势。与 PCSK9 相比,PCSK9 小鼠的病变中 SMCs 含量较高(p<0.05),胶原含量较高(p<0.05),而巨噬细胞的积累无差异。在左、右颈动脉中,PCSK9 存在于由中膜和内膜 SMCs 占据的区域。与 PCSK9 细胞相比,从 PCSK9 中分离的 SMCs 显示出更高水平的α-平滑肌肌动蛋白(α-SMA;2.24±0.36 倍;p<0.01)和肌球蛋白重链 II(MHC-II;8.65±1.55 倍;p<0.01),以及更低水平的钙调蛋白 mRNA(-54±14%;p<0.01)。PCSK9 细胞的增殖速度较慢,迁移能力受损,细胞周期的 G1/S 进展受损。通过逆转录病毒感染 PCSK9 SMCs 重建 PCSK9 表达,导致α-SMA 下调(-56±2%;p<0.01),MHC-II 下调(-45%±25.5 倍:p=0.06),钙调蛋白下调(-25%±0.8 倍:p<0.05)和钙调蛋白 mRNA 诱导(1.46±0.3 倍;p<0.05)。与 PCSK9 重建细胞相比,PCSK9 SMCs 的增殖率显著降低。
综上所述,本研究结果表明,PCSK9 通过维持 SMC 合成表型、增殖和迁移,可能在动脉壁中发挥促动脉粥样硬化作用。